MacroGenics gets that sinking feeling
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six month’s share price gains.
CytomX delivers a pancreatic surprise
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
Calliditas puts a brave face on setanaxib failure
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Glycomimetics down and out on upro miss
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
